News | Intra-Vascular Ultrasound (IVUS) | March 13, 2018

Infraredx Highlights Value of IVUS + NIRS for Detecting Lipid Core Plaque at ACC.18

Presentation bolsters company’s upcoming studies in IVUS + NIRS imaging including its highly-anticipated PROSPECT II and Lipid-Rich Plaque Study findings  

Infraredx Highlights Value of IVUS + NIRS for Detecting Lipid Core Plaque at ACC.18

March 13, 2018 –  Infraredx, a company that works in intravascular imaging for mapping coronary artery disease, today presented a poster at the American College of Cardiology (ACC) 67th Annual Scientific Session supporting the value of combination intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) imaging technology to identify lipid core plaque (LCP), an underlying cause of serious cardiac events. In the poster presentation, IVUS +NIRS demonstrated efficiencies in locating LCP within arteries, indicating the technology may be a better predictor of major adverse cardiac events (MACE) than the current methodology standard set forth by the PROSPECT study.

“This analysis validates the use of dual-modality IVUS + NIRS catheters to clearly pinpoint LCP with increased efficiency compared to IVUS alone,” said Jason Bottiglieri, president and CEO of Infraredx. “Unlike other imaging technologies, NIRS can readily distinguish areas of stable plaque from potentially dangerous LCP, which may enable cardiologists to more accurately predict and ultimately prevent serious heart attacks.”

At ACC, March 10-12, 2018, Infraredx presented Poster #241: A Correlative Study of NIRS Lipid Core Burden Index Versus Histological Plaque Disease Arc in Human Coronary Autopsy Specimens.

Study Methodology and Results

  • The PROSPECT Study found in a sub-study that the plaque disease arc via transverse IVUS was an additional independent predictor of non-culprit lesion of MACE. However, the area under the curve (AUC) parameter that was observed in the study was low (0.64) and the methodology only included use of gray-scale IVUS. 
  • Infraredx utilized a similar disease arc concept in an IVUS + NIRS autopsy study to reveal the benefits and limitations of the disease arc concept. Since underlying pathological truths can be known in an autopsy study, the degree to which disease arc finds lipid core plaques could be studied, as well as novel methods incorporating the unique IVUS + NIRS chemogram map of vessel lipid core could also be explored.
  • The study concluded that quickly locating areas of LCP with NIRS, and then assessing the disease arc on IVUS cross-sections of interest may be more targeted than use of the IVUS disease arc alone. It also may be more clinically efficient due to the automated and immediate generation of the NIRS chemogram.

“PROSPECT demonstrated that vulnerable plaques can be detected with IVUS technology, but with only modest predictive ability,” said Gregg Stone, M.D., Columbia University Medical Center and New York-Presbyterian Hospital. “As demonstrated in this study, NIRS offers the potential to further discriminate plaques, which are likely to be particularly high-risk such as those with high lipid content, a hypothesis that is being tested in ongoing PROSPECT II and LRP studies.”

For more information: www.infraredx.com

Related Content

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.

Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...
AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021
Feature | ACC | May 18, 2021 | Dave Fornell, Editor
The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announce
To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

News | ACC | February 09, 2021 | By Dave Fornell, Editor
UPDATE Feb 22, 2021 — ...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle